Imidazo [1, 2-b] pyridazine compound, preparation method thereof and application of PI3K inhibitor
By developing novel structure imidazo[1,2-b]pyridazine compounds, using Miyaura and Suzuki reactions to prepare 3-heterocyclic-6-arylbenzenesulfonamide-substituted compounds, the existing PI3K inhibitors were solved In the treatment of drug resistance and toxicity problems in cancer, significant inhibition and economical preparation of a variety of tumor cells have been achieved.
Patent Information
- Application Number
- CN202310509280.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-08
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2043-05-08
AI Technical Summary
Existing PI3K inhibitors have drug resistance and toxicity problems in the treatment of cancer, and their efficacy is limited, making it difficult to significantly prolong patient survival.
A class of novel structure imidazo[1,2-b]pyridazine compounds were developed to prepare 3-heterocyclic-6-arylbenzenesulfonamide through specific synthetic routes such as Miyaura reaction and Suzuki coupling reaction. Substituted compounds, used as PI3K inhibitors.
This compound significantly inhibits a variety of tumor cells at the cellular level, has potentially efficient and economical preparation characteristics, shows a wide range of market applications and development prospects, and may overcome the drug resistance and toxicity problems of existing PI3K inhibitors.
Smart Images

Figure BDA0004216733970000021 
Figure BDA0004216733970000022 
Figure BDA0004216733970000023
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular relates to imidazo[1,2-b]pyridazine compounds and preparation methods thereof, and applications of PI3K inhibitors. Background Art
[0002] PI3K (phosphatidylinositol 3-kinase) is a family of enzymes involved in cellular functions (such as cell growth, proliferation, differentiation, motility, survival and intracellular transport). It is part of the intracellular signaling pathway PI3K / Akt / mTOR pathway, which is important in regulating the cell cycle. PI3K can activate phosphorylation and activate Akt, locating it in the plasma membrane. Akt can have many downstream effects, such as activating cAMP response element binding protein (cyclic-AMP response binding protein, CREB), inhibiting the tumor suppressor gene p27, locating FOXO (Forkhead Box O) in the cytoplasm, etc.
[0003] Studies have shown that the PI3K pathway is mutated or amplified in a variety of cancers, including breast cancer, gastric cancer, ovarian cancer, colorectal cancer, prostate cancer, glioblastoma, and endometrial cancer. Therefore, elevated PI3K signaling is considered a hallmark of cancer. Many PI3K pathway-targeted therapies have been tested in clinical trials for tumor treatment. In addition, diseases or conditions associated with PI3K signaling also include metabolic disorders, neurodegenerative diseases, and inflammatory diseases.
[0004] Drugs that target PI3K proteins are called PI3K inhibitors. Although some progress has been made in the research and development of therapeutic PI3K inhibitors for cancer and immune disorders, there are still many problems that need to be solved: some PI3K inhibitors show drug resistance, long-term use does not significantly improve patient survival, or show severe toxicity. Despite this, due to the iconic role of the PI3K pathway in cancer, it is still necessary to develop new PI3K inhibitors. Therefore, the development of new PI3K inhibitors is of great significance to improving efficacy, overcoming drug resistance, and increasing indications. Summary of the invention
[0005] The technical problem to be solved by the present invention is to provide imidazo[1,2-b]pyridazine compounds with novel structure, simple preparation and good effect, preparation method thereof and application of PI3K inhibitors.
[0006] In order to solve the above technical problems, the present invention adopts the following technical solutions:
[0007] An imidazo[1,2-b]pyridazine compound, which is a compound conforming to the general formula (I) or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate or prodrug thereof;
[0008]
[0009] In the general formula (I), A is a substituted phenyl group and B is a heterocycle;
[0010] The substituted phenyl group is one of the following substituents:
[0011]
[0012] The heterocyclic ring is one of the following substituents:
[0013]
[0014] The above-mentioned imidazo[1,2-b]pyridazine compound is one of the following compounds LYB1-LYB30,
[0015]
[0016]
[0017] Pharmaceutically acceptable salts include salts of compounds of general formula (I) with acids and metal ions; the acid is galactaric acid, D-glucuronic acid, glycerophosphoric acid, hippuric acid, isethionic acid, lactobionic acid, maleic acid, 1,5-naphthalene disulfonic acid, naphthalene-2-sulfonic acid, pivalic acid, terephthalic acid, thiocyanic acid, bile acid, n-dodecyl sulfuric acid, benzenesulfonic acid, citric acid, D-glucose, glycolic acid, lactic acid, malic acid, malonic acid, mandelic acid, phosphoric acid, propionic acid, hydrochloric acid, sulfuric acid, tartaric acid, succinic acid, formic acid, hydroiodic acid, hydrobromic acid Acid, methanesulfonic acid, niacin, nitric acid, orotic acid, oxalic acid, picric acid, L-pyroglutamic acid, saccharinic acid, salicylic acid, gentisic acid, p-toluenesulfonic acid, valeric acid, palmitic acid, sebacic acid, stearic acid, lauric acid, acetic acid, adipic acid, carbonic acid, 4-benzenesulfonic acid, ethanedisulfonic acid, ethylsuccinic acid, fumaric acid, 3-hydroxynaphthalene-2-carboxylic acid, 1-hydroxynaphthalene-2-carboxylic acid, oleic acid, undecylenic acid, ascorbic acid, camphoric acid, camphorsulfonic acid, dichloroacetic acid, ethanesulfonic acid; the metal ions are sodium ions, potassium ions, and calcium ions.
[0018] Use of the above-mentioned imidazo[1,2-b]pyridazine compounds in the preparation of PI3K inhibitors.
[0019] Application of the above-mentioned imidazo[1,2-b]pyridazine compounds in the preparation of drugs for treating PI3K-related diseases.
[0020] PI3K-related diseases include malignant tumors, diabetes, cardiovascular diseases, and nervous system diseases; malignant tumors include lung adenocarcinoma (A549), gastric adenocarcinoma (SGC7901), cervical cancer (HeLa), liver cancer, bile duct cancer, colon cancer, and breast cancer.
[0021] The preparation method of the above-mentioned imidazo[1,2-b]pyridazine compounds is carried out according to the following reaction scheme:
[0022]
[0023] The preparation method of the above-mentioned imidazo[1,2-b]pyridazine compound comprises the following steps:
[0024] <1> Compound (III) is prepared by reacting compound (II) with 4-bromoaniline;
[0025] <2> Compound (IV) is prepared by Miyaura reaction of compound (III) with bis(boronic acid) pinacol ester under anhydrous and oxygen-free conditions;
[0026] <3> The compound (VI) is prepared by reacting the compound (V) with bromoacetaldehyde diethyl acetal;
[0027] <4> Compound (VII) is prepared by reacting compound (VI) with N-bromosuccinimide (NBS);
[0028] <5> Compound (VIII) is prepared by Suzuki coupling reaction of compound (VII) with 1-methylpyrazole-4-boric acid pinacol ester, 4-pyridineboric acid pinacol ester or 5-methylfuran-2-boric acid pinacol ester under anaerobic conditions;
[0029] <6> Compound (I) is prepared by Suzuki coupling reaction of compound (IV) and compound (VIII) under anaerobic conditions.
[0030] step <1> In the method, the acid-binding agent is pyridine, the reaction solvent is pyridine, tetrahydrofuran and water, and the reaction temperature is room temperature;
[0031] step <2> In the method, the base is potassium acetate, the catalyst is [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride, the reaction solvent is 1,4-dioxane, and the reaction temperature is 80°C to 90°C;
[0032] step <3> In the method, the acid is hydrogen bromide, the reaction solvent is 90% ethanol, and the reaction temperature is 100°C to 110°C;
[0033] step <4> In the reaction, the acid is trifluoroacetic acid, the reaction solvent is chloroform or dichloromethane, and the reaction temperature is room temperature;
[0034] step <5> In the method, the base is potassium carbonate, the catalyst is tetrakis(triphenylphosphine)palladium, the reaction solvent is 1,4-dioxane and water, and the reaction temperature is 90°C to 100°C;
[0035] step <6> In the method, the base is potassium carbonate, the catalyst is tetrakis(triphenylphosphine)palladium, the reaction solvent is 1,4-dioxane and water, and the reaction temperature is 95°C to 105°C.
[0036] The inventors have obtained a class of 3-heterocyclic-6-arylbenzenesulfonamide substituted imidazo[1,2-b]pyridazine compounds through reasonable design, which are compounds conforming to the general formula (I) or pharmaceutically acceptable salts, enantiomers, diastereomers, tautomers, solvates or prodrugs thereof;
[0037]
[0038] In addition, the inventors have also established a preparation method for the corresponding compounds. The compounds have the characteristics of novel structure and simple preparation. Experimental studies have shown that the imidazo[1,2-b]pyridazine compounds of the present invention exhibit significant inhibitory activity on various tumor cells such as A549, SGC7901, and Hela at the cellular level, and are expected to be developed into a new, highly effective, and economically simple to prepare PI3K inhibitor, which has a wide range of market applications and development prospects. DETAILED DESCRIPTION
[0039] The reaction route of the 3-heterocyclic-6-arylbenzenesulfonamide substituted imidazo[1,2-b]pyridazine compound of the present invention is as follows. To further illustrate how to implement the present invention, the following is an illustration through specific examples. Wherein, unless otherwise specified, the raw materials used are all commercially available products, and the methods used are all known methods.
[0040]
[0041] Example 1. Preparation of intermediate compounds (IV-1 to 10) (Compounds (IV) in the following examples were prepared in this way).
[0042] When A is hour,
[0043] Intermediates (IV) were prepared according to the following route:
[0044]
[0045] in,
[0046] Preparation of compound IV-1
[0047] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-1 (1.66g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-1 (1.81g, 5.55mmol, 95%) by silica gel column chromatography as a yellow-white solid.
[0048] III-1 (1.00 g, 3.07 mmol), pinacol borate (1.17 g, 4.60 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.22 g, 0.31 mmol), and potassium acetate (1.27 g, 9.20 mmol) were added into a branched reaction flask in sequence, the air in the reaction flask was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-1 (which was directly used as the reaction raw material for preparing compounds LYB1, LYB11, and LYB21 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0049] Preparation of compound IV-2
[0050] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-2 (1.7g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-2 (1.82g, 5.51mmol, 95%) by silica gel column chromatography as a yellow-white solid.
[0051] III-2 (1.00 g, 3.03 mmol), diboronic acid pinacol ester (1.15 g, 4.54 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (0.22 g, 0.31 mmol), and potassium acetate (1.27 g, 9.20 mmol) were added to a branched reaction flask in sequence, the air in the reaction flask was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-2 (which was directly used as the reaction raw material for preparing compounds LYB-2, LYB-12, and LYB-22 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0052] Preparation of compound IV-3
[0053] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-3 (1.85g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-3 (1.95g, 5.51mmol, 96%) by silica gel column chromatography as a yellow-white solid.
[0054] III-3 (1.00 g, 2.87 mmol), diboronic acid pinacol ester (1.09 g, 4.31 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (0.21 g, 0.29 mmol), and potassium acetate (1.19 g, 8.62 mmol) were added to a branched reaction flask in sequence, the air in the reaction flask was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-3 (which was directly used as the reaction raw material for preparing compounds LYB-3, LYB-13, and LYB-23 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0055] Preparation of compound IV-4
[0056] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-4 (1.85g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-4 (1.95g, 5.51mmol, 96%) by silica gel column chromatography as a yellow-white solid.
[0057] III-4 (1.00 g, 2.87 mmol), diboronic acid pinacol ester (1.09 g, 4.31 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (0.21 g, 0.29 mmol), and potassium acetate (1.19 g, 8.62 mmol) were added to a branched reaction bottle in sequence, the air in the reaction bottle was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-4 (which was directly used as the reaction raw material for preparing compounds LYB-4, LYB-14, and LYB-24 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0058] Preparation of compound IV-5
[0059] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-5 (2.1g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-5 (2.1g, 5.81mmol, 94%) by silica gel column chromatography as a yellow-white solid.
[0060] III-5 (1.00 g, 2.61 mmol), pinacol borate (1.00 g, 3.92 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.19 g, 0.26 mmol), and potassium acetate (1.08 g, 7.84 mmol) were added to a branched reaction flask in sequence, the air in the reaction flask was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-5 (which was directly used as the reaction raw material for preparing compounds LYB-5, LYB-15, and LYB-25 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0061] Preparation of compound IV-6
[0062] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-6 (2.13g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-6 (2.1g, 5.52mmol, 95%) by silica gel column chromatography as a yellow-white solid.
[0063] III-6 (1.00 g, 2.63 mmol), pinacol borate (1.00 g, 3.95 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.19 g, 0.26 mmol), and potassium acetate (1.09 g, 7.89 mmol) were added to a branched reaction bottle in sequence, the air in the reaction bottle was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-6 (which was directly used as the reaction raw material for preparing compounds LYB-6, LYB-16, and LYB-26 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0064] Preparation of compound IV-7
[0065] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-7 (1.8g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-7 (1.95g, 5.7mmol, 98%) by silica gel column chromatography as a yellow-white solid.
[0066] III-7 (1.00 g, 2.92 mmol), pinacol borate (1.11 g, 4.38 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.21 g, 0.29 mmol), and potassium acetate (1.21 g, 8.77 mmol) were added to a branched reaction flask in sequence, the air in the reaction flask was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-7 (which was directly used as the reaction raw material for preparing compounds LYB-7, LYB-17, and LYB-27 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0067] Preparation of compound IV-8
[0068] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-8 (2.27g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-8 (2.1g, 5.3mmol, 91%) by silica gel column chromatography as a yellow-white solid.
[0069] III-8 (1.00 g, 2.52 mmol), pinacol borate (0.96 g, 3.79 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.18 g, 0.25 mmol), and potassium acetate (1.05 g, 7.57 mmol) were added to a branched reaction flask in sequence, the air in the reaction flask was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-8 (which was directly used as the reaction raw material for preparing compounds LYB-8, LYB-18, and LYB-28 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0070] Preparation of compound IV-9
[0071] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-9 (1.93g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-9 (2g, 5.60mmol, 96%) by silica gel column chromatography as a yellow-white solid.
[0072] III-9 (1.00 g, 2.80 mmol), bipyralidin (1.07 g, 4.20 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.20 g, 0.27 mmol), and potassium acetate (1.16 g, 8.40 mmol) were added to a branched reaction flask in sequence, the air in the reaction flask was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-9 (which was directly used as the reaction raw material for preparing compounds LYB-9, LYB-19, and LYB-29 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0073] Preparation of compound IV-10
[0074] First, dissolve 4-bromoaniline (1g, 5.81mmol) in a reaction vessel with 10ml of pyridine. Dissolve compound II-10 (2.01g, 8.72mmol) in 10ml of pyridine and slowly drop it into the reaction vessel through a constant pressure dropping funnel under ice bath conditions. After the addition, transfer the reaction vessel to room temperature and stir overnight. Concentrate under reduced pressure to remove part of the pyridine, dilute with tetrahydrofuran: water (4:1, v / v), adjust to pH = 2.0 with hydrochloric acid, and separate III-10 (2g, 5.46mmol, 94%) by silica gel column chromatography as a yellow-white solid.
[0075] III-10 (1.00 g, 2.73 mmol), pinacol borate (1.04 g, 4.10 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (0.20 g, 0.27 mmol), and potassium acetate (1.13 g, 8.19 mmol) were added to a branched reaction flask in sequence, the air in the reaction flask was replaced with nitrogen, and the solvent 1,4-dioxane was quickly added. The reaction was placed in an 85°C oil bath for 8 hours, cooled to room temperature, ethyl acetate was added and filtered through diatomaceous earth, the filtrate was washed with saturated brine, and the organic phase was concentrated under reduced pressure to obtain a brown solid compound IV-10 (which was directly used as the reaction raw material for preparing compounds LYB-10, LYB-20, and LYB-30 and was directly put into the next step reaction, and the yield was calculated as 100%).
[0076] Example 2. Preparation of intermediate compounds (VIII-1, VIII-2, VIII-3) (Compounds (VIII-1, VIII-2, VIII-3) in the following examples are prepared in this way).
[0077] When B is When the intermediates (VIII-1, VIII-2, VIII-3) are prepared by the following route:
[0078]
[0079] in,
[0080] Preparation of compound (VIII-1)
[0081] Compound V (2 g, 15.44 mmol) was dissolved in 90% ethanol, and bromoacetaldehyde diethyl acetal (2.79 ml, 18.53 mmol) and 5 ml of hydrobromic acid were added in sequence. The mixture was reacted at 103 °C overnight, washed with saturated sodium bicarbonate solution, extracted with ethyl acetate, and the solvent was removed by rotary evaporation to obtain compound VI (2.3 g, 97%) as a yellow-white solid.
[0082] Compound VI (2 g, 13.02 mmol) was dissolved in chloroform, and NBS (3.48 g, 19.54 mmol) and trifluoroacetic acid (2 ml) were added in sequence. The mixture was reacted at room temperature for 6 h. The reaction was quenched with saturated sodium bicarbonate solution, and the organic phase was removed by rotary evaporation. The residue was extracted with ethyl acetate and purified by silica gel column chromatography to obtain VII (3 g, 99%) as a yellow-white solid.
[0083] Compound VII (1 g, 4.30 mmol), 1-methylpyrazole-4-boronic acid pinacol ester (0.99 g, 4.73 mmol), tetrakis(triphenylphosphine)palladium (0.4 mg, 0.34 mmol), potassium carbonate (1.78 g, 12.91 mmol) were added to a branched reaction bottle in sequence, and the air in the bottle was replaced with nitrogen. Then 1,4-dioxane: water (8:2) was added to dissolve, and the mixture was transferred to 95°C for reaction for 12 h, cooled to room temperature, and ethyl acetate was added to dilute the reaction system. The organic phase was concentrated under reduced pressure and purified by silica gel column chromatography (petroleum ether: ethyl acetate = 3:1) to obtain a yellow-green solid VIII-1 (0.8 g, 80%). After detection and analysis, its spectral data are as follows:
[0084] 1 H NMR (500 MHz, DMSO-d 6 )δ8.35(s,1H),8.19(d,J=9.4Hz,1H),8.13(s,1H),8.09(s,1H),7.28(d,J=9.4Hz,1H),3.95(s,3H).
[0085] Preparation of compound (VIII-2)
[0086] The preparation of compound VII is the same as the above method.
[0087] Compound VII (1 g, 4.30 mmol), 4-pyridineboronic acid pinacol ester (0.98 g, 4.73 mmol), tetrakis(triphenylphosphine)palladium (0.4 mg, 0.34 mmol), potassium carbonate (1.78 g, 12.91 mmol) were added to a branched reaction bottle in sequence, and the air in the bottle was replaced with nitrogen. Then 1,4-dioxane: water (8:2) was added to dissolve, and the mixture was transferred to 100°C for reaction for 12 h, cooled to room temperature, and ethyl acetate was added to dilute the reaction system. The organic phase was concentrated under reduced pressure and purified by silica gel column chromatography to obtain a yellow-white solid VIII-2 (0.6 g, 60%). After detection and analysis, its spectral data are as follows:
[0088] 1 H NMR (600 MHz, DMSO-d 6)δ8.75–8.68(m,2H),8.60(s,1H),8.37(d,J=9.5Hz,1H),8.16–8.09(m,2H),7.54(d,J=9.5Hz,1H).
[0089] Preparation of compound (VIII-3)
[0090] The preparation of compound VII is the same as the above method.
[0091] Compound VII (1 g, 4.30 mmol), 5-methylfuran-2-boronic acid pinacol ester (0.98 g, 4.73 mmol), tetrakis(triphenylphosphine)palladium (0.4 mg, 0.34 mmol), potassium carbonate (1.78 g, 12.91 mmol) were added to a branched reaction bottle in sequence, and the air in the bottle was replaced with nitrogen. Then 1,4-dioxane: water (8:2) was added to dissolve, and the mixture was transferred to 95°C for reaction for 12 h, cooled to room temperature, and ethyl acetate was added to dilute the reaction system. The organic phase was concentrated under reduced pressure and purified by silica gel column chromatography to obtain a yellow solid VIII-3 (0.7 g, 69%). After detection and analysis, its spectral data are as follows:
[0092] 1 H NMR(600MHz,Chloroform-d)δ8.03(s,1H),7.85(dd,J=23.4,9.4Hz,1H),7.12(d,J=3 .2Hz, 1H), 6.99 (d, J = 9.3Hz, 1H), 6.11 (dd, J = 3.3, 1.3Hz, 1H), 2.35 (d, J = 1.1Hz, 3H).
[0093] Example 3. Preparation of 4-methyl-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-1)
[0094] Compound VI-1 (1.14 g, 3.05 mmol), VIII-1 (0.64 g, 2.75 mmol), tetrakis(triphenylphosphine)palladium (0.35 g, 0.31 mmol), potassium carbonate (0.9 g, 6.5 mmol) were added to a branched reaction bottle in sequence, and the air in the bottle was replaced with nitrogen. Then 1,4-dioxane: water (8:2) was added to dissolve, and the reaction was carried out at 100°C for 16 hours. The reaction system was diluted with ethyl acetate, filtered through diatomaceous earth, washed with saturated sodium chloride solution, and the organic phase was concentrated under reduced pressure and purified by silica gel column chromatography to obtain yellow solid LYB-1. After detection and analysis, its spectral data are as follows:
[0095] 1 H NMR (600 MHz, DMSO-d6 )δ10.67(s,1H),8.50(d,J=202.2Hz,1H),8.08(s,1H),8.19(d,J=4.8Hz,1H),8.18(s,1H),8.10(d,J=2.7Hz,2H),8.08( s,1H),7.74(d,J=8.1Hz,2H),7.71(d,J=9.5Hz,1H),7.38(d,J=8.0Hz,2H),7.34–7.30(m,2H),3.99(s,3H),2.33(s,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ151.05,144.02,140.19,138.23,137.09,136.84,131.27,130.73,130.32,128 .56,128.40,127.20,126.28,122.72,119.86,114.89,109.90,39.25,21.42.HRMS m / z 445.1444[M+H] + .
[0096] Example 4. Preparation of 4-fluoro-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-2)
[0097] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0098] 1 H NMR(600MHz,Chloroform-d)δ10.81(s,1H),8.55(s,1H),8.24(s,2H),8.16(d,J=8.3Hz,2H),7.96(dd,J=8.5,5.1Hz, 2H),7.76(d,J=9.5Hz,1H),7.64–7.52(m,2H),7.5(d,J=8.7Hz,2H),7.49(s,1H),7.38(d,J=8.4Hz,2H),4.04(s,3H). 13 C NMR (151 MHz, DMSO-d 6)δ164.88(d,J=251.4Hz),150.97,139.94,136.87,136.34,131.33,131.08(d,J=12.1Hz),130.23 (d,J=9.7Hz),129.00,128.62,128.44,126.36,120.24,117.13(d,J=22.7Hz),114.87,39.26.HRMS m / z 449.1190[M+H] + .
[0099] Example 5. Preparation of 2,5-difluoro-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-3)
[0100] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0101] 1 H NMR (600 MHz, DMSO-d 6 )δ11.20(s,1H),8.50(s,1H),8.20(d,J=10.7Hz,1H),8.19(s,1H),8.13(s,1H),8.11(d,J=6.8Hz,2H),7.78–7. 74(m,1H),7.72(d,J=9.5Hz,1H),7.61(m,1H),7.55(dt,J=9.1,4.7Hz,1H),7.35(d,J=8.3Hz,2H),3.99(s,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ136.85,131.33,128.70,128.40,126.32,119.90,117.47(d,J=26.6Hz),114.90,109.89,39.25.HRMS m / z 467.1194[M+H] + .
[0102] Example 6. Preparation of 2,4-difluoro-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-4)
[0103] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0104] 1 H NMR (600 MHz, DMSO-d 6)δ11.12(s,1H),8.50(d,J=8.0Hz,1H),8.20(d,J=7.6Hz,1H),8.19(s,1H),8.12(d,J=8.1Hz,2H),8.11(s,1H).8.0 2(td,J=8.6,6.0Hz,1H),7.72(d,J=9.5Hz,1H),7.58(ddd,J=11.2,9.0,2.5Hz,1H),7.36–7.28(m,3H),4.00(s,3H).
[0105] 13 C NMR (151 MHz, DMSO-d 6 )δ159.41(d,J=257.4Hz),158.65,150.97,139.34,138.25,136.85,133.04(d,J=11.0Hz),131.32,131.12,128.61(d,J=12 .8Hz),128.41,126.31,124.29,122.74,119.81,114.89,113.04(d,J=20.7Hz),109.89,106.72(t,J=26.0Hz),39.25.HRMS m / z 467.1097[M+H] + .
[0106] Example 7. Preparation of 5-chloro-2,4-difluoro-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-5)
[0107] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0108] 1 H NMR (600 MHz, DMSO-d 6 )δ11.24(s,1H),8.51(s,1H),8.21(d,J=10.3Hz,1H),8.21(s,1H),8.13(dd,J=12.9,6.9 Hz,4H),7.87(t,J=9.4Hz,1H),7.74(d,J=9.5Hz,1H),7.36(d,J=8.5Hz,2H),4.00(s,3H). 13 C NMR (151 MHz, DMSO-d 6)δ143.50,139.07,138.27,136.87,131.96,131.38,128.76,128.43,126.33,120.13,114.93,109.89,108.52,39.25.HRMS m / z 501.0704[M+H] + .
[0109] Example 8. Preparation of N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)-4-(trifluoromethyl)benzenesulfonamide (LYB-6)
[0110] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0111] 1 H NMR (600 MHz, DMSO-d 6 )δ11.00(s,1H),8.51(s,1H),8.20(s,1H),8.13(d,J=8.3Hz,2H),8.08(d,J=8.2Hz,2H),8.01(d,J=8.3 Hz,2H),7.72(d,J=9.4Hz,1H),7.57(t,J=8.7Hz,1H),7.51(s,1H),7.36(d,J=8.3Hz,2H),4.00(s,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ150.93,143.84,139.49,136.90,131.41,128.72,128.49,128.16,127.24,120.47,114.92,39.25.HRMS m / z 499.1160[M+H] + .
[0112] Example 9. Preparation of 4-methoxy-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-7)
[0113] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0114] 1 H NMR (600 MHz, DMSO-d 6)δ10.62(s,1H),8.48(s,1H),8.18(s,1H),8.16–8.14(m,2H),8.07(d,J=8.4Hz,2H),7.82–7.78 (m,2H),7.69(d,J=9.5Hz,1H),7.36–7.31(m,2H),7.10–7.07(m,2H),3.98(s,3H),3.78(s,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ163.05,151.05,140.32,136.87,131.53,129.40,128.54,119.80,114.99,56.09,39.25.HRMS m / z461.1381[M+H] + .
[0115] Example 10. Preparation of 4-trifluoromethoxy-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-8)
[0116] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0117] 1 H NMR (600 MHz, DMSO-d 6 )δ10.88(s,1H),8.51(s,1H),8.21(d,J=10.3Hz,2H),8.14(d,J=2.1Hz,1H),8.12(d,J=5.0Hz,2H) ,8.03–7.97(m,2H),7.74(d,J=9.6Hz,1H),7.62(d,J=8.4Hz,2H),7.38–7.33(m,2H),4.00(s,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ151.67,150.94,139.69,138.86,138.24,136.84,131.32,131.20,129.81, 128.66,128.39,126.30,122.72,122.05,120.28,119.39,114.86,39.23.HRMS m / z 515.1112[M+H] + .
[0118] Example 11. Preparation of 4-nitro-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-9)
[0119] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0120] 1 H NMR (600 MHz, DMSO-d 6 )δ11.05(s,1H),8.49(s,1H),8.41(d,J=8.5Hz,2H),8.22–8.15(m,3H),8. 14–8.05(m,4H),7.72(d,J=9.5Hz,1H),7.35(d,J=8.3Hz,2H),3.99(s,3H). 13 C NMR (126 MHz, DMSO-d 6 )δ150.92,150.41,145.45,139.54,138.25,136.85,134.70,134.62,131.40,131.37,130. 72,128.75,128.72,128.39,126.35,125.28,122.73,120.65,114.86,109.88,39.26.HRMS m / z 476.1139[M+H] + .
[0121] Example 12. Preparation of 2,4,5-trifluoro-N-(4-(3-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-10)
[0122] The title compound was synthesized in a similar manner to Example 3. After detection and analysis, its spectral data are as follows:
[0123] 1 H NMR (600 MHz, DMSO-d 6 )δ11.24(s,1H),8.50(s,1H),8.20(d,J=9.8Hz,2H),8.14(s,1H),8.12(d,J=7.5Hz,2H),8.07(q,J= 8.4Hz,1H),7.89(td,J=10.0,5.8Hz,1H),7.73(d,J=9.5Hz,1H),7.35(d,J=8.3Hz,2H),3.99(s,3H). 13 C NMR (126 MHz, DMSO-d 6)δ150.95,139.07,138.25,136.84,131.95(d,J=9.7Hz),131.33(d,J=5.7Hz),129.22(d,J=11.9Hz),128.7 1,128.40,126.34,122.73,119.99,119.44(d,J=21.3Hz),114.88,109.90,110.82–107.34(m),39.26.HRMS m / z 485.1001[M+H] + .
[0124] Example 13. Preparation of 4-methyl-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-11)
[0125] Compound VI-1 (1.14 g, 3.05 mmol), VIII-2 (0.63 g, 2.75 mmol), tetrakis(triphenylphosphine)palladium (0.35 mg, 0.31 mmol), potassium carbonate (0.9 mg, 6.5 mmol) were added to a branched reaction bottle in sequence, and the air in the bottle was replaced with nitrogen. Then 1,4-dioxane: water (8:2) was added to dissolve, and the reaction was carried out at 105°C for 16 hours. The reaction system was diluted with ethyl acetate, filtered through diatomaceous earth, washed with saturated sodium chloride solution, and the organic phase was concentrated under reduced pressure and purified by silica gel column chromatography to obtain yellow-white solid LYB-11. After detection and analysis, its spectral data are as follows:
[0126] 1 H NMR (600 MHz, DMSO-d 6 )δ10.70(s,1H),8.74–8.70(m,2H),8.55(s,1H),8.31(d,J=9.6Hz,1H),8.28–8.24(m,2H),8.10–8.04( m,2H),7.88(d,J=9.6Hz,1H),7.77–7.72(m,2H),7.38(d,J=8.2Hz,2H),7.35–7.31(m,2H),2.33(s,3H). 13 C NMR (151 MHz, DMSO-d 6 )δ151.41,150.67,144.04,140.87,140.45,137.07,135.98,135.82,130. 33,128.65,127.19,126.92,125.32,119.94,119.81,117.18,21.42.HRMS m / z 442.1330[M+H] + .
[0127] Example 14. Preparation of 4-fluoro-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-12)
[0128] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0129] 1 H NMR (600 MHz, DMSO-d 6 )δ9.07(s,1H),8.74–8.69(m,2H),8.55(s,1H),8.32(d,J=9.6Hz,1H),8.28–8.24(m,2H),8.12 –8.06(m,2H),7.95–7.91(m,2H),7.89(d,J=9.6Hz,1H),7.48–7.41(m,2H),7.38–7.30(m,2H). 13 C NMR (151 MHz, DMSO-d 6 )δ164.89(d,J=251.9Hz),150.99(d,J=107.2Hz),140.20,136.31,135.96,135.82,131.14(d,J=9.9H z),130.63,130.24(d,J=9.7Hz),129.00,128.70,126.93,120.18,117.19(d,J=7.2Hz),117.06.HRMS m / z 446.1089[M+H] + .
[0130] Example 15. Preparation of 2,5-difluoro-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-13)
[0131] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0132] 1 H NMR (600 MHz, DMSO-d 6)δ13.18(s,1H),8.73–8.70(m,2H),8.56(s,2H),8.32(d,J=9.6Hz,1H),8.15–8.08(m,2H),8.02– 7.97(m,2H),7.89(d,J=9.5Hz,1H),7.77(d,J=5.1Hz,1H),7.62–7.59(m,2H),7.38–7.33(m,2H). 13 C NMR (126 MHz, DMSO-d 6 )δ151.68,151.30,150.63,139.93,138.81,135.98,130.83,129.82,128.75, 126.93,125.32,122.06,120.23,119.94,119.31(d,J=24.0Hz),117.16.HRMS m / z 464.0987[M+H] + .
[0133] Example 16. Preparation of 2,4-difluoro-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-14)
[0134] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0135] 1 H NMR (600 MHz, DMSO-d 6 )δ11.15(s,1H),8.73(d,2H),8.56(s,1H),8.32(d,J=9.5Hz,1H),8.27(d,J=5.0Hz,2H),8.09(d,J=8. 5Hz,2H),8.02(td,J=8.6,6.1Hz,1H),7.89(d,J=9.5Hz,1H),7.59–7.48(m,2H),7.33(d,J=8.5Hz,2H). 13 C NMR (126 MHz, DMSO-d 6 )δ151.03(d,J=88.6Hz),135.92(d,J=15.0Hz),133.01(d,J=11.3Hz),130.61,12 8.74,126.98,119.90(d,J=27.4Hz),117.21,112.94,106.82(d,J=25.5Hz).HRMS m / z464.0991[M+H] + .
[0136] Example 17. Preparation of 5-chloro-2,4-difluoro-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-15)
[0137] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0138] 1 H NMR (600 MHz, DMSO-d 6 )δ11.26(s,1H),8.74–8.69(m,2H),8.55(s,1H),8.32(d,J=9.5Hz,1H),8.28–8.24 (m,2H),8.16–8.08(m,3H),7.88(s,1H),7.85(t,J=9.5Hz,1H),7.38–7.33(m,2H). 13 C NMR (126 MHz, DMSO-d 6 )δ156.78(d,J=12.5Hz),151.01(d,J=87.0Hz),139.40,135.93(d,J=12.7Hz),134.71(d,J=10.1Hz),13 1.95,132.80–129.73(m),128.87(d,J=10.1Hz),126.99,125.36,120.09,119.99,117.24,108.53.HRMS m / z
[0139] 498.0600[M+H] + .
[0140] Example 18. Preparation of 4-trifluoromethyl-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-16)
[0141] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0142] 1 H NMR (600 MHz, DMSO-d 6)δ11.01(s,1H),8.73–8.70(m,2H),8.56(s,1H),8.32(d,J=9.6Hz,1H),8.29–8.25(m,2H),8.11(d,J= 8.3Hz,2H),8.07(d,J=8.2Hz,2H),8.01(d,J=8.3Hz,2H),7.89(d,J=9.6Hz,1H),7.36(d,J=8.3Hz,2H). 13 C NMR (126 MHz, DMSO-d 6 )δ151.27,150.63,143.84,139.79,135.90(d,J=12.3Hz),133.34,133.08,130. 96,128.78,128.15,127.22(q,J=3.7Hz),126.96,120.41,120.00,117.16.HRMS m / z496.1047[M+H] + .
[0143] Example 19. Preparation of 4-methoxy-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-17)
[0144] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0145] 1 H NMR (600 MHz, DMSO-d 6 )δ10.63(s,1H),8.72(d,J=5.2Hz,2H),8.55(s,1H),8.31(d,J=9.6Hz,1H),8.26(d,J=5.2Hz,2H),8.07(d,J=8.3 Hz,2H),7.88(d,J=9.6Hz,1H),7.80(d,J=8.6Hz,2H),7.33(d,J=8.3Hz,2H),7.10(d,J=8.7Hz,2H),3.79(s,3H). 13 C NMR (126 MHz, DMSO-d 6 )δ163.06,151.41,150.65,140.86,140.56,135.88(d,J=24.2Hz),131.49,130. 25,129.41,128.62,126.89,119.85(d,J=24.0Hz),117.17,115.02,56.10.HRMS m / z 458.1293[M+H] + .
[0146] Example 20. Preparation of 4-trifluoromethoxy-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-18)
[0147] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0148] 1 H NMR (600 MHz, DMSO-d 6 )δ10.89(s,1H),8.73–8.70(m,3H),8.56(s,1H),8.32(d,J=9.5Hz,1H),8.27(d,J=5.2Hz,2H),8.1 3–8.07(m,2H),8.02–7.95(m,2H),7.89(d,J=9.6Hz,1H),7.61(d,J=8.4Hz,2H),7.38–7.32(m,2H). 13 C NMR (126 MHz, DMSO-d 6 )δ151.83–151.52(m),151.31,150.65,139.99,138.85,135.91(d,J=13.5Hz),130.80, 129.81,128.75,126.95,125.35,122.06,121.27,120.24,119.97,119.22,117.16.HRMS m / z512.0998[M+H] + .
[0149] Example 21. Preparation of 4-nitro-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-19)
[0150] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0151] 1 H NMR (600 MHz, DMSO-d 6 )δ10.36(s,1H),8.74–8.71(m,2H),8.55(s,1H),8.36–8.22(m,3H),8.05(d,J=8.4Hz ,2H),7.89(d,J=9.6Hz,1H),7.51–7.46(m,2H),7.32–7.27(m,2H),6.59–6.55(m,2H). 13C NMR (126 MHz, DMSO-d 6 )δ153.54,151.36,150.66,140.12,136.25(d,J=3.1Hz),130.67,130.29,130.21 ,129.27,128.71,128.49,126.93,120.18,119.98,119.31,117.24,117.06.HRMS m / z 473.1025[M+H] + .
[0152] Example 22. Preparation of 2,4,5-trifluoro-N-(4-(3-(pyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-20)
[0153] The title compound was synthesized in a similar manner to Example 13. After detection and analysis, its spectral data are as follows:
[0154] 1 H NMR (600 MHz, DMSO-d 6 )δ11.28(s,1H),8.84–8.66(m,2H),8.57(s,1H),8.36–8.22(m,3H),8.09(dd,J=1 8.6,8.2Hz,3H),7.90(d,J=10.1Hz,1H),7.59–7.55(m,1H),7.35(d,J=8.3Hz,2H). 13 C NMR (126 MHz, DMSO-d 6 )δ151.37,150.62,148.46–139.14(m),135.84,130.73,128.78,126.99,1 20.12–119.77(m),119.41(d,J=21.7Hz),117.21,110.53–107.57(m).HRMS m / z 482.0889[M+H] + .
[0155] Example 23. Preparation of 4-methyl-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-21)
[0156] Compound VI-1 (1.14 g, 3.05 mmol), VIII-3 (0.64 g, 2.75 mmol), tetrakis(triphenylphosphine)palladium (0.35 mg, 0.31 mmol), potassium carbonate (0.9 mg, 6.5 mmol) were added to a branched reaction bottle in sequence, and the air in the bottle was replaced with nitrogen. Then 1,4-dioxane: water (8:2) was added to dissolve, and the reaction was carried out at 95°C for 16 hours. The reaction system was diluted with ethyl acetate, filtered through diatomaceous earth, washed with saturated sodium chloride solution, and the organic phase was concentrated under reduced pressure and purified by silica gel column chromatography to obtain yellow solid LYB-21. After detection and analysis, its spectral data are as follows:
[0157] 1 H NMR (600 MHz, DMSO-d 6 )δ10.68(s,1H),8.22(d,J=9.6Hz,1H),8.05(d,J=9.3Hz,3H),7.75(t,J=7.7Hz,3H),7.37(d,J=8.1H z,2H),7.32(d,J=8.3Hz,2H),7.21(d,J=3.2Hz,1H),6.33(d,J=3.2Hz,1H),2.39(s,2H),2.32(s,3H). 13 C NMR (126 MHz, DMSO-d 6 )δ151.91,151.30,144.00,142.08,140.36,138.77,137.09,131.99,131.91,130.30, 129.26,129.17,128.48,127.21,126.43,119.82,109.24,108.50,21.41,13.80.HRMS m / z445.1327[M+H] + .
[0158] Example 24. Preparation of 4-fluoro-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-22)
[0159] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0160] 1 H NMR (600 MHz, DMSO-d 6)δ10.77(s,1H),8.25(d,J=9.6Hz,1H),8.08(d,J=8.3Hz,2H),8.05(s,1H),7.92(dd,J=8.7,5.1Hz,2H),7.79(d,J= 9.5Hz,1H),7.43(t,J=8.6Hz,2H),7.32(d,J=8.3Hz,2H),7.23(d,J=3.2Hz,1H),6.35(d,J=3.1Hz,1H),2.40(s,3H). 13 C NMR (126 MHz, DMSO-d 6 )δ164.90(d,J=252.0Hz),151.94,151.27,142.08,140.02,138.79,136.28(d,J=3.0Hz),131.99,131.91,1 30.25(d,J=9.5Hz),129.27,129.17,128.56,126.48,120.20,117.13(d,J=22.8Hz),109.26,108.51,13.81.
[0161] Example 25. Preparation of 2,5-difluoro-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-23)
[0162] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0163] 1 H NMR (600 MHz, DMSO-d 6 )δ11.21(s,1H),8.34–8.22(m,1H),8.10(d,J=8.5Hz,2H),7.83–7.74(m,2H ),7.67–7.48(m,3H),7.35(d,J=8.6Hz,2H),6.37–6.34(m,1H),2.41(s,3H). 13 C NMR (126 MHz, DMSO-d 6)δ159.57–153.07(m),151.96,151.28,146.79,137.13,131.99,131.91,129.27,129.18,128.75–128.53(m),127 .83,123.73(d,J=114.8Hz),120.14,119.92(d,J=14.9Hz),118.89,117.60,117.38,109.31,108.53,14.54.HRMS m / z467.0980[M+H] + .
[0164] Example 26. Preparation of 2,4-difluoro-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-24)
[0165] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0166] 1 H NMR (600 MHz, DMSO-d 6 )δ11.13(s,1H),8.26(d,J=9.5Hz,1H),8.09(d,J=8.3Hz,2H),8.06(s,1H),8.03(td,J=8.6,6.0Hz,1H),7.80(d ,J=9.5Hz,1H),7.64–7.54(m,2H),7.33(d,J=8.5Hz,2H),7.24(d,J=3.2Hz,1H),6.37–6.34(m,1H),2.41(s,3H). 13 CNMR (126MHz, DMSO-d 6 )δ157.70(d,J=245.3Hz),151.96,151.27,146.78,142.07,139.51,137.13,133.95,133.17–132.35(m),127.83 ,124.81–122.45(m),119.82(d,J=8.9Hz),117.60,117.39,115.81,113.13,109.29,108.53,106.72,13.82.HRMS m / z 467.0982[M+H] + .
[0167] Example 27. Preparation of 5-chloro-2,4-difluoro-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-25)
[0168] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0169] 1 H NMR (600 MHz, DMSO-d 6 )δ11.25(s,1H),8.27(d,J=9.5Hz,1H),8.13(dd,J=17.1,8.1Hz,3H),7.86(t,J=9.5Hz,1H),7.81(d,J=9 .4Hz,1H),7.63(s,1H),7.35(d,J=8.4Hz,2H),7.24(d,J=3.3Hz,1H),6.36(d,J=3.1Hz,1H),2.41(s,3H). 13 C NMR (126 MHz, DMSO-d 6 )δ151.96,151.25,142.09,139.14,133.59,132.78,132.50(d,J=2.7Hz),131.95(d,J=9.8Hz),131.17,129.2 2(d,J=11.7Hz),128.68,127.42–124.47(m),120.09,117.54–116.46(m),115.80,109.29,108.52,13.82.HRMS m / z 501.0601[M+H] + .
[0170] Example 28. Preparation of 4-trifluoromethyl-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-26)
[0171] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0172] 1 H NMR (600 MHz, DMSO-d 6 )δ9.06(s,1H),8.87–8.54(m,2H),8.30(d,J=9.6Hz,1H),8.16(d,J=8.2Hz,2H),8.08(s,1H),7.98(d,J=8.1 Hz,2H),7.87(d,J=9.6Hz,1H),7.53–7.31(m,2H),7.24(d,J=3.2Hz,1H),6.36(d,J=3.2Hz,1H),2.41(s,3H). 13C NMR (126 MHz, DMSO-d 6 )δ151.98,151.27,142.07,139.84,138.83,133.59,132.78,132.51(d,J=2.7Hz),131.91,131.30–130. 53(m),129.82,129.23(d,J=11.8Hz),128.62,126.52,122.06,120.27,115.80,109.28,108.52,13.81.
[0173] Example 29. Preparation of 4-methoxy-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-27)
[0174] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0175] 1 H NMR (600 MHz, DMSO-d 6 )δ10.62(d,J=5.7Hz,1H),8.22(d,J=9.6Hz,1H),8.07–8.03(m,2H),7.77(dq,J=21.2,6.7,5.2Hz,3H),7.2 9(dd,J=31.0,8.3Hz,3H),7.21(s,1H),7.09(d,J=8.5Hz,2H),6.37–6.31(m,1H),3.78(s,3H),2.39(s,3H). 13 C NMR (126 MHz, DMSO-d 6 )δ163.05,151.92,151.32,142.07,140.46,138.76,131.53(d,J=5.7Hz),130.81,130.38,129.42, 128.46,126.41,121.49,119.76,115.75,114.97(d,J=6.5Hz),109.24,108.50,56.09,13.79.HRMS m / z 461.1269[M+H] + .
[0176] Example 30. Preparation of 4-trifluoromethoxy-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-28)
[0177] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0178] 1 H NMR (600 MHz, DMSO-d 6 )δ8.98(s,1H),8.29(dd,J=21.4,9.4Hz,3H),8.14–8.11(m,2H),8.00(s,1H),7.65–7.53(m, 2H),7.44(dd,J=19.6,9.5Hz,3H),7.06(d,J=3.3Hz,1H),6.35(d,J=3.2Hz,1H),2.40(s,3H). 13 C NMR (126 MHz, DMSO-d 6 )δ152.25(d,J=72.7Hz),148.07,147.44,141.27,139.84,138.81,135.11, 133.59,132.77,132.50(d,J=2.8Hz),131.99,131.91,131.46,129.82,129. 27,129.17,128.59(d,J=3.6Hz),128.36,122.05,121.54(d,J=6.9Hz),120 .26,119.99,118.85,109.72,108.52(d,J=3.1Hz),13.80(d,J=2.4Hz).HRMS m / z 515.0998[M+H] + .
[0179] Example 31. Preparation of 4-nitro-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-29)
[0180] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0181] 1 H NMR (600 MHz, DMSO-d 6 )δ11.05(s,1H),8.41(dd,J=7.7,5.6Hz,2H),8.27(d,J=9.5Hz,1H),8.10(dd,J=8.7,1.6Hz,3H),8.07(s,1 H),7.80(d,J=9.6Hz,1H),7.35(d,J=8.6Hz,2H),7.23(d,J=3.2Hz,1H),6.35(d,J=3.4Hz,1H),2.41(s,3H).13 C NMR (126 MHz, DMSO-d 6 )δ151.96,151.19,150.44,145.26,142.06,139.44,132.73,131.30,128.77,128.67 ,126.53,125.25(d,J=9.8Hz),122.98,120.61,115.76,109.26,108.50,13.81.HRMS m / z476.1020[M+H] + .
[0182] Example 32. Preparation of 2,4,5-trifluoro-N-(4-(3-(5-methylfuran-2-yl)imidazo[1,2-b]pyridazin-6-yl)phenyl)benzenesulfonamide (LYB-30)
[0183] The title compound was synthesized in a similar manner to Example 23. After detection and analysis, its spectral data are as follows:
[0184] 1 H NMR (600 MHz, DMSO-d 6 )δ11.26(s,1H),8.27(d,J=9.1Hz,1H),8.09(dd,J=18.9,6.6Hz,3H),7.89(td,J=10.0,5.9Hz,1H),7.81(d,J=9 .6Hz,1H),7.66–7.53(m,1H),7.36(d,J=8.4Hz,2H),7.24(d,J=3.2Hz,1H),6.36(d,J=3.2Hz,1H),2.41(s,3H). 13 C NMR (126 MHz, DMSO-d 6 )δ157.12–152.53(m),151.97,151.27,142.51–137.84(m),131.99,131.91,131.23–130.80(m),129.26,129.17 ,128.65,126.52,121.51,119.94,119.56,119.39,115.92–115.67(m),109.39–108.69(m),108.51,13.81.HRMS m / z 485.0883[M+H] + .
[0185] Example 33 Cellular Activity Test
[0186] The inhibitory rate of drugs on different tumor cells was detected by MTT method. The cells required for biological evaluation were cultured in DMEM medium. 10% Australian fetal bovine serum and 5% double antibody (penicillin plus streptomycin) were added to all cells during culture. The cells were incubated at 37°C and 5% CO 2 Cultured in an incubator. Tumor cells in the logarithmic growth phase were inoculated into 96-well plates. Among them, 1000 cells were inoculated per well of A549 cells; 1500 cells were inoculated per well of SGC7901 cells; 1000 cells were inoculated per well of HeLa cells, and 150μl of cell solution containing culture medium was added to each well. In this MTT experiment, 1-2 replicates were performed in each group. The positive control drug Omipalisib and the compound to be tested were dissolved in DMSO, diluted to a mother solution with a concentration of 50mM, and an appropriate amount of mother solution was taken to dilute it to 1μM. After 24h of culture, the drug was added, and the culture was continued in an incubator for 72h. After 72 hours, the 96-well plate was removed, 15μl of 5μg / ml MTT solution was added to each well, incubated at 37℃ for 4h, the MTT solution was aspirated, 150μl / well of DMSO was added, and the shaker was kept away from light for 10min. The OD value was detected by an enzyme marker, and the detection wavelength was 490nm. The inhibition rate was calculated according to the following formula and the results are shown in the table:
[0187] Cell inhibition rate (%) = [1-(OD value of experimental group-OD value of blank well) / (OD value of control group-OD value of blank well)] × 100%
[0188] Inhibition rate of compounds LYB-1 to LYB-30 on various organelles at a concentration of 1 μM (%)
[0189]
[0190]
Claims
1. An imidazo[1,2-b]pyridazine compound, characterized in that A compound according to the general formula (I) or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate or prodrug thereof; In the general formula (I), A is a substituted phenyl group and B is a heterocycle; The substituted phenyl group is one of the following substituents: The heterocyclic ring is one of the following substituents:
2. The imidazo[1,2-b]pyridazine compound according to claim 1, characterized in that is one of the following compounds LYB1-LYB30, 3. The imidazo[1,2-b]pyridazine compound according to claim 1, characterized in that: The pharmaceutically acceptable salts include salts of the compound of general formula (I) with acids and metal ions; the acid is galactaric acid, D-glucuronic acid, glycerophosphoric acid, hippuric acid, isethionic acid, lactobionic acid, maleic acid, 1,5-naphthalene disulfonic acid, naphthalene-2-sulfonic acid, pivalic acid, terephthalic acid, thiocyanic acid, bile acid, n-dodecyl sulfuric acid, benzenesulfonic acid, citric acid, D-glucose, glycolic acid, lactic acid, malic acid, malonic acid, mandelic acid, phosphoric acid, propionic acid, hydrochloric acid, sulfuric acid, tartaric acid, succinic acid, formic acid, hydroiodic acid, hydrochloric acid Bromic acid, methanesulfonic acid, nicotinic acid, nitric acid, orotic acid, oxalic acid, picric acid, L-pyroglutamic acid, saccharinic acid, salicylic acid, gentisic acid, p-toluenesulfonic acid, valeric acid, palmitic acid, sebacic acid, stearic acid, lauric acid, acetic acid, adipic acid, carbonic acid, 4-benzenesulfonic acid, ethanedisulfonic acid, ethylsuccinic acid, fumaric acid, 3-hydroxynaphthalene-2-carboxylic acid, 1-hydroxynaphthalene-2-carboxylic acid, oleic acid, undecylenic acid, ascorbic acid, camphoric acid, camphorsulfonic acid, dichloroacetic acid, ethanesulfonic acid; the metal ions are sodium ions, potassium ions, and calcium ions.
4. Use of the imidazo[1,2-b]pyridazine compound according to claim 1 in the preparation of a PI3K inhibitor.
5. Use of the imidazo[1,2-b]pyridazine compound according to claim 1 in the preparation of a drug for treating PI3K-related diseases.
6. The use according to claim 5, characterized in that: The PI3K-related diseases are malignant tumors, diabetes, cardiovascular diseases, and nervous system diseases; the malignant tumors are lung adenocarcinoma, gastric adenocarcinoma, cervical cancer, liver cancer, bile duct cancer, colon cancer, and breast cancer.
7. The method for preparing the imidazo[1,2-b]pyridazine compound according to claim 1, characterized in that Proceed according to the following reaction route:
8. The method for preparing the imidazo[1,2-b]pyridazine compound according to claim 7, characterized in that The following steps are involved: <1> Compound (III) is prepared by reacting compound (II) with 4-bromoaniline; <2> Compound (IV) is prepared by Miyaura reaction of compound (III) with bis-boronic acid pinacol ester under anhydrous and oxygen-free conditions; <3> The compound (VI) is prepared by reacting the compound (V) with bromoacetaldehyde diethyl acetal; <4> Compound (VII) is prepared by reacting compound (VI) with N-bromosuccinimide; <5> Compound (VIII) is prepared by Suzuki coupling reaction of compound (VII) with 1-methylpyrazole-4-boric acid pinacol ester, 4-pyridineboric acid pinacol ester or 5-methylfuran-2-boric acid pinacol ester under anaerobic conditions; <6> Compound (I) is prepared by Suzuki coupling reaction of compound (IV) and compound (VIII) under anaerobic conditions.
9. The method for preparing the imidazo[1,2-b]pyridazine compound according to claim 8, characterized in that: step <1> In the method, the acid-binding agent is pyridine, the reaction solvent is pyridine, tetrahydrofuran and water, and the reaction temperature is room temperature; step <2> In the method, the base is potassium acetate, the catalyst is [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride, the reaction solvent is 1,4-dioxane, and the reaction temperature is 80°C to 90°C; step <3> In the method, the acid is hydrogen bromide, the reaction solvent is 90% ethanol, and the reaction temperature is 100°C to 110°C; step <4> In the reaction, the acid is trifluoroacetic acid, the reaction solvent is chloroform or dichloromethane, and the reaction temperature is room temperature; step <5> In the method, the base is potassium carbonate, the catalyst is tetrakis(triphenylphosphine)palladium, the reaction solvent is 1,4-dioxane and water, and the reaction temperature is 90°C to 100°C; step <6> In the method, the base is potassium carbonate, the catalyst is tetrakis(triphenylphosphine)palladium, the reaction solvent is 1,4-dioxane and water, and the reaction temperature is 95°C to 105°C.
Citation Information
Patent Citations
Imidazopyridazines as pi3k lipid kinase inhibitors
CN101528748A
3, 6-disubstituted-imidazo [1, 2-B] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-A] pyrimidines as phosphatidylinositol-3-kinase inhibitors
CN101678026A
Substituted imidazopyridazines as PI3K lipid kinase inhibitors
CN101754968A
Bicyclic heterocyclic derivatives as MNK1 and MNK2 modulators and uses thereof
WO2013147711A1
